TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
Reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting
Clearance of INDs for four TCR-Ts, including a TCR-T for PRAME, in support of use of multiple TCRs in combination for the solid tumor clinical trial
Related news for (TCRX)
- MoBot alert highlights: NASDAQ: FLNC, NASDAQ: TORO, NYSE: AMBI, NASDAQ: TCRX, NYSE: UAMY (10/01/25 02:00 PM)
- MoBot’s Stock Market Highlights – 10/01/25 01:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/03/25 07:00 PM
- Breaking News: MoBot’s Latest Update as of 06/03/25 06:00 PM
- Breaking News: MoBot’s Latest Update as of 06/03/25 05:00 PM